ICER Publishes Evidence Report on Targeted Immune Modulator Therapies for Ulcerative Colitis

-- All assessed therapies provide significant health benefits, but all are priced, even after rebates, at levels above common thresholds for cost-effectiveness --

-- At the upcoming September 24 virtual meeting, the California Technology Assessment Forum will review the evidence, hear further testimony from stakeholders, and deliberate over these treatments’ comparative clinical effectiveness, other potential benefits, and long-term value for money --

Read More